应用SELDI-TOF-MS技术筛选早期胃癌的血清诊断标志物

陈海莲; 纪托; 周中银

doi:10.3969/j.issn.1671-038X.2018.07.05

应用SELDI-TOF-MS技术筛选早期胃癌的血清诊断标志物

- 1. 湖北省黄石市疾病预防控制中心, 湖北黄石 435000;
- 2. 湖北省黄石人福医院, 湖北黄石 435004;
- 3. 湖北省人民医院, 湖北武汉 430000

详细信息

作者简介:
陈海莲,女,硕士研究生,副主任医师,研究方向:普内科专业

通讯作者: 纪托,E-mail:17976376@qq.com

中图分类号: R735.2

收稿日期: 2018-03-15

Surface-enhanced laser desorption ionization time-of-flight mass spectrometry used to screen serum diagnostic markers of early gastric cancer

- 1. Huangshi Manicipal Center for Disease Control and Prevention, Huangshi 435000, China;
- 2. Huangshi Renfu Hospital, Huangshi 435004, China;
- 3. Hubei Provincial People's Hospital, Wuhan 430000, China

More Information

Corresponding author: JI Tuo, E-mail: 17976376@qq.com

Received Date: 15 March 2018

摘要

摘要: [目的]筛选早期胃癌可能存在的特异性蛋白标记物。[方法]采用CM10蛋白质芯片和表面增强激光解析电离飞行时间质谱（SELDI-TOF-MS）技术，对胃黏膜高级别上皮内瘤变（HGIEN）患者，Ⅰ/Ⅱ期胃癌患者及Ⅲ/Ⅳ期胃癌患者各24例的血清蛋白质谱进行分析。[结果]与高级别上皮内瘤变（HGIEN）患者对比，胃癌组有37种蛋白存在表达差异。这37种蛋白中有9种在Ⅰ/Ⅱ期胃癌组与Ⅲ/Ⅳ期胃癌组存在不同丰度的表达（P<0.05），其中2687.5 Da、6271.2 Da及6779.3 Da表达差异显著（P<0.01），2687.5 Da在高级别上皮内瘤变（HGIEN）组、Ⅰ/Ⅱ期胃癌组及Ⅲ/Ⅳ期胃癌组中表达上调，6271.2 Da及6779.3 Da在高级别上皮内瘤变（HGIEN）组、Ⅰ/Ⅱ期胃癌组及Ⅲ/Ⅳ期胃癌组中表达下调。以这三个蛋白质构建预测诊断模型，经盲法验证，该模型的灵敏度为77.78%，特异度为88.89%。[结论]这3个蛋白或将成为早期胃癌诊断的特异性生物蛋白标志物。
- SELDI-TOF-MS技术 /
- 高级别上皮内瘤变(HGIEN) /
- 胃癌
Abstract: [Objective] To screen specific protein markers in patients with early gastric cancer.[Methods] CM10 protein chip and Surfaceenhanced laser desorption ionization timeofflight mass spectrometry(SELDI-TOF-MS) were used to analyze the serum protein profiles of patients(n=24) with gastric high-grade intraepithelial neoplasia(HGIEN), Ⅰ/Ⅱ gastric cancer and Ⅲ/Ⅳ gastric cancer.[Results] Compared with patients of high-grade intraepithelial neoplasia(HGIEN), there were 37 protein expression differences in the gastric cancer group.Nine of the 37 proteins showed different abundance expression in stage Ⅰ/Ⅱ gastric cancer group and stage Ⅲ/Ⅳ gastric cancer group(P<0.05), among which 2687.5 Da, 6271.2 Da and 6779.3 Da were significantly different(P<0.01)), 2687.5 Da was up-regulated, 6271.2 Da and 6779.3 Da were down-regulated in high-grade intraepithelial neoplasia(HGIEN) group, Ⅰ/Ⅱ gastric cancer group and Ⅲ/Ⅳ gastric cancer group.With these three proteins, a predictive diagnostic model was constructed and verified by blind method.The sensitivity and specificity of the model were 77.78% and 88.89% respectively.[Conclusion] These three proteins may be specific biological protein markers for the diagnosis of early gastric cancer.
- SELDI-TOF-MS /
- High-grade intraepithelial neoplasia(HGIEN) /
- gastric cancer

HTML全文

参考文献(19)

[1]	Crew KD, Neugut AI.Epidemiology of gastric cancer[J].World J Gastroenterol, 2006, 12(3):354-362.
[2]	纪托, 陈海莲, 周中银.胃癌腹膜转移的血清蛋白质特异性生物标志物的研究[J].中国中西医结合消化杂志, 2017, 25(9):702-708.
[3]	梁玉屏, 刘维花, 杨落落等.早期胃癌的筛查[J].中华内科杂志, 2014, 53(4):325-326.
[4]	Ferlay J, Soerjomataram I, Dikshit R, et al.Cancer incidence and mortality worldwide:sources, methods and major patterns in GLOBOCAN 2012[J].Int J Cancer, 2015, 136(5):359-386.
[5]	Li B, Liu H Y, Guo S H, et al.Microsatellite instability of gastric cancer and precancerous lesions[J].Int J Clin Exp Med, 2015, 8(11):21138-21144.
[6]	Zhang H, Hou Y, Xu L, et al.Cytoplasmic Drosha Is Aberrant in Precancerous Lesions of Gastric Carcinoma and Its Loss Predicts Worse Outcome for Gastric Cancer Patients[J].Dig Dis Sci, 2016, 61(4):1080-1090.
[7]	Wang X W, Wu Y, Wang D, et al.MicroRNA network analysis identifies key microRNAs and genes associated with precancerous lesions of gastric cancer[J].Genet Mol Res, 2014, 13(4):8695-8703.
[8]	Stengel F, Aebersold R, Robinson CV.Joining forces:integrating proteomics and cross-linking with the mass spectrometry of intact complexes[J].Mol Cell Proteomics, 2012, 11(3):R111.014027.
[9]	Xu S Y, Liu Z, Ma W J, et al.New potential biomarkers in the diagnosis of esophageal squamous cell carcinoma[J].Biomarkers, 2009, 14(5):340-346.
[10]	郑顺贞, 邹声泉.比较蛋白质组学在肿瘤标志物研究中的应用[J].中国普外基础与临床杂志, 2008, 17(2):147-149.
[11]	Bakry R, Rainer M, Huck C W, et al.Protein profiling for cancer biomarker discovery using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and infrared imaging:a review[J].Anal Chim Acta., 2011, 690(1):26-34.
[12]	Boggio K J, Obasuyi E, Sugino K, et al.Recent advances in single-cell MALDI mass spectrometry imaging and potential clinical impact[J].Expert Rev Proteomics, 2011, 8(5):591-604.
[13]	Qiu M Z, Lin J Z, Wang Z Q, et al.Cutoff value of carcinoembryonic antigen and carbohydrate antigen 19-9elevation levels for monitoring recurrence in patients with resectable gastric adenocarcinoma[J].Int J Biol Markers, 2009, 24(4):258-264.
[14]	Marrelli D, Roviello F, De Stefano A, et al.Prognostic significance of CEA, CA 19-9and CA 72-4preoperative serum levels in gastric carcinoma[J].Oncology, 1999, 57(1):55-62.
[15]	Carpelan-Holmstorm M, Louhimo J, Stenman U H, Alfthan H and Haglund C:CEA, CA 19-9and CA72-4improve the diagnostic accuracy in gastrointestinal cancers[J].Anticancer Res, 2002, 22(4):2311-2316.
[16]	Koike H, Ichikawa D, Ikoma H, et al.Comparison of serum aberrant methylation and conventional tumor markers in gastric cancer patients[J].Hepatogastroenterology, 2005, 52(64):1293-1296.
[17]	Fung E T, Weinberger S R, Gavin E, et al.Bioinformatics approaches in clinical proteomics[J].Expert Rev Proteomics, 2005, 2(6):847-862.
[18]	Roboz J.Mass spectrometry in diagnostic oncoproteomics[J].Cancer Invest, 2005, 23(5):465-478.
[19]	Posadas E M, Simpkins F, Liotta L A, et al.Proteomic analysis for the early detection and rational treatment of cancer-realistic hope?[J].Ann Oncol, 2005, 16(1):16-22.